DATE
Regeneron crumples under the weight of missed Eylea expectations
Regeneron, United States Food and Drug Administration, earnings, Eylea, decline, Sales – occupational activity
AbbVie’s Rinvoq cleared for giant cell arteritis in US
Giant Cell Arteritis, Rinvoq, upadacitinib, Approved, Janus kinase, Inhibitor, United States Food and Drug Administration, Steroids
FDA decision on Stealth’s Barth syndrome drug delayed, again
United States Food and Drug Administration, 3-Methylglutaconic aciduria type 2, Decision, Elamipretide
AACR25: Boehringer touts new durability data for zongertinib in targeted lung cancer
Malignant neoplasm of lung, AACR25, cellular targeting, Boehringer, Non-Small Cell Lung Carcinoma, Zongertinib, Zongertinib, durability
Caribou cuts 32% of staff, further purges pipeline to focus on 2 oncology CAR-T prospects
Reindeer, CAR-T, Staff, Neoplasms, Cell Therapy, Allogeneic CRISPR-edited Anti-CD19 CAR-T Cells CB-010, Clustered Regularly Interspaced Short Palindromic Repeats, Leukemia, Myelocytic, Acute, United States Food and Drug Administration, 32%
Mercks Gardasil sales sink further amid China market pressure
Market, China, Gardasil, Gardasil sales, Pressure- physical agent, Growth, China
Sanofi’s Altuviiio closing in on blockbuster status, Dupixent sales surge
Altuviiio, Sales – occupational activity, sanofi, Dupixent, United States Food and Drug Administration
New NIH grant rules override the Civil Rights Act of 1964, barring recipients from DEI activities
United States National Institutes of Health, recipients, NIH, Policy, Diversity, Changing, Condition, civil, federal, civil, protections, recipients, Israeli (population group), Civil Rights Act, 1964